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Abstract
Tuberculosis remains a global health problem with an enormous burden of disease, estimated at 
10.4 million new cases in 2015. To stop the tuberculosis epidemic, it is critical that we interrupt 
tuberculosis transmission. Further, the interventions required to interrupt tuberculosis transmission 
must be targeted to high-risk groups and settings. A simple cascade for tuberculosis transmission 
has been proposed in which (1) a source case of tuberculosis (2) generates infectious particles (3) 
that survive in the air and (4) are inhaled by a susceptible individual (5) who may become infected 
and (6) then has the potential to develop tuberculosis. Interventions that target these events will 
interrupt tuberculosis transmission and accelerate the decline in tuberculosis incidence and 
mortality. The purpose of this article is to provide a high-level overview of what is known about 
tuberculosis transmission, using the tuberculosis transmission cascade as a framework, and to set 
the scene for the articles in this series, which address specific aspects of tuberculosis transmission.
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Tuberculosis remains a global health problem with an enormous burden of disease, 
estimated at 10.4 million new cases in 2015, of which 10% were among children and 12% 
involved human immunodeficiency virus (HIV) coinfection [1]. In 2015, there were an 
estimated 1.8 million deaths due to tuberculosis, including HIV-associated tuberculosis 
deaths, making tuberculosis the leading cause of death from an infectious disease [1]. Latent 
Mycobacterium tuberculosis infection is the reservoir of the tuberculosis epidemic. The 
global burden of M. tuberculosis infection has recently been reestimated at 24% [2].
The global rate of decline in tuberculosis incidence is currently 1.5% and will need to 
increase to 4%–5% by 2020 and then to 10% per year by 2025 to meet the World Health 
Organization End TB Strategy targets (Figure 1)[3]. Interrupting tuberculosis transmission is 
central to achieving the reductions in tuberculosis incidence required to meet the End TB 
targets. A rate of decline of 10% per year is thought to be achievable, as this was observed 
during the 1950s and 1960s in Western Europe, where comprehensive tuberculosis control 
efforts, which included infection control and treatment of M. tuberculosis infection and all 
forms of tuberculosis, were intensified and universal health coverage and socioeconomic 
development were expanded [1]. Specific examples include declines in tuberculosis 
mortality and incidence observed after the second world war in England, Wales, and the 
Netherlands, where improved socioeconomic conditions and better nutrition and living 
standards were thought to be major factors contributing to improved tuberculosis control [4]. 
Tuberculosis case notifications among children <5 years of age declined in New York and 
London but not in Cape Town over the century between 1912 and 2012 despite similar, 
contemporaneous tuberculosis control strategies, which included the introduction of 
chemotherapy in the mid-1950s. This observation suggests that socioeconomic development 
played a greater role than the introduction of chemotherapy in reducing tuberculosis 
transmission [5]. Mathematical modeling suggests that it is possible to rapidly reduce 
tuberculosis incidence and mortality in high-burden countries, including those with a high 
HIV prevalence, if a comprehensive strategy of combination treatment and prevention is 
implemented at scale, rapidly [6]. Modeling further suggests that development of new drugs, 
diagnostic assays, and vaccines will be essential to accelerate progress toward tuberculosis 
elimination [7]. We have a unique opportunity in the era of the United Nations Sustainable 
Development Goals to address poverty and other social determinants of tuberculosis while 
simultaneously scaling up currently available effective tuberculosis control interventions to 
interrupt tuberculosis transmission and thereby maximize impact on reducing tuberculosis 
incidence and mortality. In addition, we should continue to conduct research to optimize 
delivery of effective interventions, as well as develop new tools that can maximize 
interrupting tuberculosis transmission.
In March 2016, the National Institutes of Health convened a workshop aimed at identifying 
the research needs for halting tuberculosis transmission, with the eventual aim of reducing 
new M. tuberculosis infections to zero. The purpose of this article is to give a high-level 
overview of the discussion at the workshop regarding what is known about tuberculosis 
transmission and to set the scene for the articles that address specific aspects of tuberculosis 
transmission. The lessons learned from studying tuberculosis transmission are also relevant 
to reducing transmission of other airborne pathogens.
Churchyard et al. Page 2
J Infect Dis. Author manuscript; available in PMC 2018 November 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
EPIDEMIOLOGY OF TUBERCULOSIS TRANSMISSION: A BRIEF HISTORY
Robert Koch discovered M. tuberculosis in 1882. William Osler, in 1909, wrote that “all 
who mix with tuberculosis patients got infected, but remained well so long as they took care 
of themselves and kept the soil in a condition unfavorable for the growth of the seed” [8]. 
Over the intervening century of tuberculosis research, our understanding of tuberculosis 
transmission and disease progression has improved: in 1920, Devoto recognized that 
healthcare workers were at risk of developing tuberculosis; in 1934, Wells described the 
falling and evaporation times for droplet nuclei [9]; and Riley, in 1961, described the 
deposition of airborne bacteria in the lung [10] and, in 1960–1962, described aerial 
dissemination of M. tuberculosis in a tuberculosis ward [11, 12]. Chapman, in 1964, 
described the social and other factors associated with tuberculosis transmission in 
tuberculosis-affected households [13].
More recent achievements (circa mid-2000s) in this area include the phylogeographical 
classification of global M. tuberculosis strains and the advent of whole-genome sequencing 
for molecular tracking of tuberculosis outbreaks.
TUBERCULOSIS TRANSMISSION CASCADE
In this series, a simple cascade for tuberculosis transmission is proposed in which (1) a 
source case of tuberculosis (2) generates infectious particles (3) that survive in the air and 
(4) are inhaled by a susceptible individual (5) who may become infected and (6) who then 
has the potential to develop tuberculosis. Interventions that target bacterial, host, or 
behavioral catalysts of transmission will interrupt tuberculosis transmission and accelerate 
the decline in tuberculosis incidence and mortality [14]. In this article, this cascade of 
tuberculosis transmission will be used to describe who is transmitting, where transmission is 
occurring, and who is susceptible to infection and to disease progression. In answering these 
questions, we can understand what it will take to stop tuberculosis transmission (Figure 2).
WHO IS TRANSMITTING?
The infectiousness and duration thereof for a person with tuberculosis depend on host and 
bacterial factors. Persons with smear-positive pulmonary tuberculosis are highly infectious, 
and the degree of infectiousness is thought to increase with the degree of smear positivity. In 
a large study of household contacts in Peru, smear-positive index cases were associated with 
a higher risk of infection among household contacts, compared with smear-negative index 
cases, regardless of the age of the household contacts [15]. Persons with smear-negative 
tuberculosis cases may, however, also transmit tuberculosis [16]. Nevertheless, scale-up of 
sputum smear microscopy has not succeeded in achieving dramatic declines in tuberculosis 
incidence. Possible reasons for the lack of impact include the poor sensitivity of smear 
microscopy, particularly among HIV-infected persons and children, and the occurrence of 
many cases of transmission before people receive a tuberculosis diagnosis and treatment.
Persons with active pulmonary or laryngeal tuberculosis generate droplet nuclei that contain 
M. tuberculosis through coughing, singing, shouting, sneezing, or any other forceful 
expiratory maneuver that shears respiratory secretions from the airways, with coughing 
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being the most efficient at generating infectious aerosols [16]. Appropriate treatment of 
individuals with infectious tuberculosis results in a rapid reduction in infectiousness [17]. 
Individuals with index tuberculosis cases who are HIV infected, particularly those with 
advanced immunosuppression, were hypothesized to be less likely than HIV-uninfected 
individuals with tuberculosis to transmit to household contacts, possibly because of a greater 
likelihood of having smear-negative tuberculosis and a shorter duration of infectiousness due 
to more rapid progression to death [18, 19].
Antiretroviral therapy reduces the risk of tuberculosis among people with HIV infection 
(PLHIV) by 67% and, if scaled up, may contribute to a reduction in tuberculosis case rates at 
a population level [20, 21]. Although there is preferential mixing of close contacts within 
age groups and sexes, in Southern Africa most M. tuberculosis infections appear to be 
associated with contact with adult men [22].
WHERE IS TRANSMISSION OCCURRING?
Robert Koch, in his Nobel Lecture, delivered in 1905, said that “tuberculosis has been called 
plainly, and quite justly, a disease of accommodation” [23], highlighting transmission of 
tuberculosis within tuberculosis-affected households. Today there is a wealth of evidence to 
support transmission of drug-susceptible and drug-resistant tuberculosis in households [15, 
24, 25]. Transmission of tuberculosis to household contacts is most likely to occur when the 
index case is smear positive and the household contacts are <15 years of age [15, 26]. 
Despite a historical focus on household transmission, the overall proportion of tuberculosis 
transmissions that occur in households is estimated to be between 8% and 19% in countries 
with a high HIV prevalence, such as South Africa and Malawi [27]. In settings with a high 
tuberculosis burden, tuberculosis transmission is therefore more likely to occur outside the 
household, in schools, public transportation settings, workplaces, healthcare facilities, 
mines, and prisons [19, 26–33]. Nevertheless, targeting tuberculosis-affected households for 
tuberculosis screening, HIV testing, and referral for treatment of tuberculosis or M. 
tuberculosis infection remains a priority because of the high prevalence of tuberculosis and 
M. tuberculosis infection among household contacts. Transmission within hospitals and 
clinics can be reduced by using the FAST approach: Finding undiagnosed tuberculosis cases 
Actively through cough surveillance and use of rapid molecular diagnostics, Separating 
safely, and providing appropriate Treatment [34]. Geographic areas with increased 
tuberculosis transmission (so-called hot spots) may be identified using geospatial mapping, 
and interventions targeted to these areas may help to interrupt transmission [25]. In a 
country with a low tuberculosis burden, such as the United States, targeting active, 
community-based screening and isoniazid preventive therapy to 2 relatively high-burden 
neighborhoods was effective in eliminating tuberculosis in the intervention neighborhoods 
[35].
WHO IS SUSCEPTIBLE?
Close contacts of infectious tuberculosis cases are susceptible to becoming infected and, if 
infected, to progressing to tuberculosis, particularly within the first year after exposure [36]. 
Among 95 contact investigation studies from countries of low and middle incomes, the 
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prevalence of M. tuberculosis infection among contacts was 51.5%. Contacts who are <5 
years of age or HIV infected have the greatest risk of developing tuberculosis [36]. Among 
countries with high burdens of tuberculosis and HIV infection, such as South Africa and 
Zambia, HIV-infected household contacts have a risk of progressing to tuberculosis that is 
almost 5-fold greater than that for HIV-uninfected household contacts [37]. In settings with a 
high tuberculosis burden, silica-exposed miners, particularly those with silicosis, have a high 
prevalence of M. tuberculosis infection [38, 39]. Many persons who are at high risk of 
developing tuberculosis can be identified on the basis of their medical history or with simple 
tests [14]. Currently, it is not possible to identify persons who have an increased risk of 
infection if exposed.
HALTING TRANSMISSION
Halting tuberculosis transmission is central to stopping the tuberculosis epidemic. As shown 
in Figure 2, it may be possible to target interventions to reduce the infectiousness or duration 
of infectiousness of tuberculosis cases, contact rates, and susceptibility of contacts. Contact 
between an infectious tuberculosis case and a susceptible person may occur because of 
clustering in space (such as in households, workplaces, and urban slums) or over time (such 
as in public transportation settings, among migrant workers, and during urbanization or 
displacement) [14]. Contact rates can be reduced through socioeconomic development 
leading to reduced crowding. Socioeconomic development also improves nutrition, reducing 
progression to tuberculosis. Improved infection control also accompanies socioeconomic 
development, particularly improved ventilation in areas where contact is likely to occur, such 
as healthcare facilities, public transportation settings, workplaces, and schools [5, 14]. 
Infectiousness and the duration of infectiousness can be reduced through early case 
detection and treatment by improving access to quality tuberculosis diagnostic and treatment 
services, use of quicker and more-sensitive diagnostic assays such as Xpert MTB/Rif, active 
case finding and linkage to care for appropriate treatment, and interventions to reduce 
attrition before starting treatment [6]. Susceptibility to tuberculosis can be reduced by 
addressing host factors such as HIV infection, diabetes, anti–tumor necrosis factor treatment, 
organ transplantation, renal dialysis, silicosis, illicit drug use, malnutrition, harmful alcohol 
use, and smoking. Susceptibility to tuberculosis can also be reduced by treating the 
underlying condition (eg, HIV infection and diabetes), by reducing key exposures (eg, silica 
dust, tobacco smoke, and indoor pollutants), and by providing preventive therapy for latent 
M. tuberculosis infection.
A number of intervention studies have attempted to reduce tuberculosis transmission at a 
population level by using combinations of case finding and preventive therapy interventions 
targeting at-risk groups or communities, with success ranging from no or minimal impact to 
large and sustained impact (Table 1) [40–51]. The variable success of the interventions in 
achieving a population-level impact may be due to poor targeting of risk groups, inadequate 
coverage, implementation of interventions that are not implemented or evaluated long 
enough to capture mass effect, and use of old tools, such as sputum microscopy.
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NEW TOOLS
Advances in technology may allow more-effective targeting of the sources of tuberculosis 
transmission. The Xpert MTB/RIF test was initially heralded as a “game changer” in the 
diagnosis of tuberculosis, owing to its greater sensitivity than sputum smear microscopy [52, 
53]. The roll out of Xpert MTB/RIF, however, has had limited impact on tuberculosis 
mortality and incidence to date, largely because of health system weaknesses, particularly 
those due to poor uptake of HIV testing and linkage to care for antiretroviral therapy. This 
highlights the need to strengthen health systems and develop new tools [54, 55]. The next-
generation Xpert MTB/Rif (Ultra) cartridge is expected to be even more sensitive and could 
be a valuable tool to identify active and infectious cases, thereby allowing the prevention of 
transmission. Modeling suggests that new tuberculosis drugs and regimens for drug-
susceptible and drug-resistant tuberculosis that are shorter and more efficacious may have a 
modest population-level impact [7, 56]. New tests for individuals with M. tuberculosis 
infection that predict who will progress to tuberculosis will allow treatment of infection to 
be targeted to those at greatest risk of developing tuberculosis [57]. Implementation of new, 
short-course regimens for treating latent M. tuberculosis infection, such as weekly high-dose 
isoniazid and rifapentine for 3 months or daily isoniazid and rifampicin for 3 months, 
potentially could have a profound effect on the tuberculosis epidemic, particularly if 
implemented at scale and coupled with active case finding and treatment of all forms of 
tuberculosis. Barriers to scaling up treatment of M. tuberculosis infection should be 
addressed, and innovative, affordable models of delivery that support scale up of treatment 
of M. tuberculosis infection should be evaluated [58]. New research tools, such as whole-
genome sequencing, could help us understand global and local tuberculosis epidemiology 
better and thereby target interventions to reduce transmission more effectively [59]. 
Similarly, tuberculosis vaccines that prevent M. tuberculosis infection or disease among 
adolescents and adults may have a profound impact on the tuberculosis epidemic [60].
CONCLUSION
Robert Koch, in his Nobel Lecture, said that “amidst the persistently great variety in the 
ways and means of combating tuberculosis, it is yet necessary to ask what measures do 
indeed best satisfy the scientific requirements” [23]. More than 100 years later, we are still 
asking the same question. Although our understanding of tuberculosis transmission has 
improved substantially, many gaps remain. Subsequent articles in this series aim to identify 
these gaps and to describe the benefits (and obstacles) to filling them. One thing is certain: if 
we wish to end tuberculosis by 2035, a massive concerted effort is required today.
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Figure 1. 
Projected acceleration in the decline of global tuberculosis incidence rates to target levels. 
From WHO END TB Strategy [3].
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Figure 2. 
Cascade of tuberculosis transmission. (Source: The Aurum Institute)
Churchyard et al. Page 11
J Infect Dis. Author manuscript; available in PMC 2018 November 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Churchyard et al. Page 12
Ta
bl
e 
1
St
ud
ie
s E
va
lu
at
in
g 
Tu
be
rc
ul
os
is 
In
te
rv
en
tio
ns
 In
te
nd
ed
 to
 A
ch
ie
v
e 
a 
Po
pu
la
tio
n-
Le
v
el
 Im
pa
ct
C
ou
nt
ry
(ie
s),
 Ye
a
r,
 R
ef
er
en
ce
(s)
Se
tti
ng
D
es
ig
n(
s)
In
te
rv
en
tio
n(
s)
O
ut
co
m
e M
ea
su
re
(s)
Fi
nd
in
g(s
)
Tu
n
isi
a,
 1
96
3 
[4
1,
 
42
]
U
rb
an
 sl
um
s (
n =
 15
3)
CR
T 
(ho
us
ing
 bl
oc
ks
)
IP
T 
fo
r 1
2 
m
o
Tu
be
rc
ul
os
is 
ca
se
 ra
te
s 
(ca
ses
/10
00
)
2.
3 
ca
se
s/1
00
0 
in
 IP
T 
ar
m
 v
s 3
.1
 in
 
pl
ac
eb
o 
ar
m
 (2
5.8
% 
red
uc
tio
n)
G
re
en
la
nd
, 1
96
6 
[4
2–
44
]
Vi
lla
ge
s (
n =
 76
)
CR
T 
(vi
lla
ge
s)
2 
co
ur
se
s o
f I
N
H
 4
00
 m
g 
tw
ic
e 
w
ee
kl
y 
fo
r 3
 m
o,
 3
 
ra
te
s 
m
o 
ap
ar
t
Cu
m
ul
at
iv
e 
ca
se
5.
7%
 in
 IP
T 
ar
m
 v
s 8
.3
%
 in
 p
la
ce
bo
 ar
m
 
(31
.3%
 re
du
cti
on
)
U
S,
 1
96
7 
[4
0,
 
41
,
 
44
]
A
la
sk
a,
 B
et
he
l c
om
m
un
iti
es
 
(n 
= 3
0)
CR
T 
(ho
us
eh
old
s)
H
ou
se
ho
ld
-w
id
e 
IP
T 
fo
r 
12
 m
o
Cu
m
ul
at
iv
e 
ca
se
 r
at
e
1.
90
%
 in
 IP
T 
ar
m
 v
s 4
.6
7%
 in
 p
la
ce
bo
 
ar
m
 (5
9.3
% 
red
uc
tio
n)
U
S,
 1
98
6 
[4
6]
O
re
go
n,
 B
ur
ns
id
e 
ar
ea
B
ef
or
e/
af
te
r 
in
te
rv
en
tio
n 
(ho
me
les
s 
sh
el
te
rs
)
M
an
da
to
ry
 tu
be
rc
ul
os
is 
sc
re
en
in
g 
an
d 
tre
at
m
en
t 
o
f t
ub
er
cu
lo
sis
 o
r M
. 
tu
be
rc
ul
os
is 
in
fe
ct
io
n 
am
o
n
g 
pe
rs
on
s u
sin
g 
ho
m
el
es
s s
he
lte
r
Ca
se
 n
ot
ifi
ca
tio
n 
ra
te
, 1
99
5 
v
s 
19
85
29
 ca
se
s/1
00
 0
00
 in
 1
99
5 
vs
 2
27
 in
 1
98
5 
(de
cli
ne
 gr
ea
ter
 th
an
 th
at 
ob
ser
ve
d 
in
 
o
th
er
 d
ist
ric
ts)
Zi
m
ba
bw
e,
 2
00
5 
[4
7]
H
ar
ar
e,
 h
ig
h-
de
ns
ity
 su
bu
rb
s 
(n 
= 4
6)
CR
T 
(su
bu
rb
s)
Tu
be
rc
ul
os
is 
sc
re
en
in
g 
v
ia
 m
ob
ile
 v
an
 o
r 
do
or
 to
 
do
or
Tu
be
rc
ul
os
is 
pr
ev
al
en
ce
; 
be
fo
re
 v
s a
fte
r i
nt
er
ve
n
tio
n 
fo
r b
ot
h 
ar
m
s c
om
bi
ne
d
6.
5 
ca
se
s/1
00
0 
at
 b
as
el
in
e v
s 3
.7
 af
te
r 
in
te
rv
en
tio
n 
(aR
R,
 0.
59
 [9
5%
 C
I, .
40
–.
89
])
Za
m
bi
a 
an
d 
So
ut
h 
A
fri
ca
, 2
00
6 
[4
8]
Co
m
m
un
iti
es
 in
 S
ou
th
 
A
fri
ca
 a
nd
 Z
am
bi
a 
(n 
= 2
4)
CR
T 
(co
mm
un
itie
s),
 
fa
ct
or
ia
l d
es
ig
n
(1)
 E
CF
 vs
 no
n-E
CF
; (
2) 
ho
us
eh
ol
d 
ca
re
 v
s n
on
–
ho
us
eh
ol
d 
ca
re
(1)
 Tu
be
rc
ul
os
is 
pr
ev
al
en
ce
, 
in
fe
ct
io
n 
in
ci
de
nc
e;
 (2
) 
tu
be
rc
ul
os
is 
pr
ev
al
en
ce
, 
in
fe
ct
io
n 
in
ci
de
nc
e
(1)
 92
7 c
ase
s o
f t
ub
erc
ulo
sis
/10
0 0
00
 in
 
EC
F 
ar
m
 v
s 7
11
 in
 n
on
-E
CF
 a
rm
 (a
RR
, 
1.
11
 [9
5%
 C
I, 
.87
–1
.42
]);
 1.
41
% 
in
fe
ct
io
n 
in
ci
de
nc
e 
in
 E
CF
 a
rm
 v
s 1
.0
5%
 
in
 n
on
-E
CF
 a
rm
 (a
RR
, 1
.36
 [9
5%
 C
I, .
59
–3
.1
4]
); 
(2)
 74
6 c
ase
s o
f 
tu
be
rc
ul
os
is/
10
0 
00
0 
in
 h
ou
se
ho
ld
 c
ar
e 
ar
m
 v
s 
83
3 
in
 n
on
–h
ou
se
ho
ld
 c
ar
e 
ar
m
 
(aR
R,
 0.
78
 [9
5%
 C
I, .
61
–1
.00
]);
 0.
87
% 
in
fe
ct
io
n 
in
ci
de
nc
e 
in
 h
ou
se
ho
ld
 c
ar
e 
ar
m
 v
s 
1.
71
%
 in
 n
on
–h
ou
se
ho
ld
 c
ar
e 
ar
m
 (R
R,
 1.
36
 [9
5%
 C
I, .
59
–3
.14
])
B
ra
zi
l, 
20
10
 [4
9]
U
rb
an
 c
om
m
un
iti
es
 (n
 = 
8)
CR
T 
(fa
v
el
as
)
Tu
be
rc
ul
os
is 
sc
re
en
in
g 
pl
us
 IP
T 
in
 h
ou
se
ho
ld
 
co
n
ta
ct
s
Tu
be
rc
ul
os
is 
in
ci
de
nc
e
35
8 
ca
se
s/1
00
 0
00
 in
 co
nt
ro
l a
rm
 v
s 3
05
 
in
 in
te
rv
en
tio
n 
ar
m
 (P
 
=
 0
.0
4)
So
ut
h 
A
fri
ca
, 2
01
1 
[2
9]
G
ol
d 
m
in
es
 (n
 = 
16
 cl
us
ter
s)
CR
T 
(m
ine
s)
Co
m
m
un
ity
-w
id
e 
tu
be
rc
ul
os
is 
sc
re
en
in
g 
an
d 
IP
T
Tu
be
rc
ul
os
is 
in
ci
de
nc
e
3.
02
 c
as
es
/1
00
 p
er
so
n-
ye
ar
s i
n 
in
te
rv
en
tio
n 
ar
m
 v
s 2
.9
5 
in
 co
nt
ro
l a
rm
 
(aR
R,
 0.
96
 [9
5%
 C
I, .
76
–1
.21
])
B
ra
zi
l, 
20
13
 [5
0]
R
io
 d
e 
Ja
ne
iro
, H
IV
 c
lin
ic
s 
(n 
= 2
9)
CR
T 
(H
IV
 cl
ini
cs)
, s
tep
 
w
ed
ge
IP
T 
pr
om
ot
io
n
In
ci
de
nc
e 
of
 tu
be
rc
ul
os
is 
al
on
e,
 in
ci
de
nc
e 
of
 
tu
be
rc
ul
os
is 
an
d 
de
at
h
1.
1 
ca
se
s o
f t
ub
er
cu
lo
sis
/1
00
 p
er
so
n-
ye
ar
s i
n 
in
te
rv
en
tio
n 
ar
m
 v
s 1
.3
1 
in
 
co
n
tr
ol
 a
rm
 (a
HR
, 0
.73
 [9
5%
 C
I, .
54
–.
99
]);
 3.
04
 ca
ses
 of
 tu
be
rcu
los
is 
an
d 
de
at
hs
/1
00
 p
er
so
n-
ye
ar
s v
s 3
.6
4 
in
 
co
n
tr
ol
 a
rm
 (a
HR
, 0
.69
 [9
5%
 C
I, .
57
–.
83
])
D
at
a 
ar
e 
ad
ap
te
d 
an
d 
ex
pa
nd
ed
 fr
om
 th
e 
ar
tic
le
 b
y 
K
ra
nz
er
 e
t a
l [
51
], 
wh
ich
 us
ed
 a 
no
ns
ys
tem
ati
c l
ite
rat
ur
e r
ev
ie
w
 a
n
d 
w
as
 th
er
ef
or
e 
no
t c
om
pr
eh
en
siv
e.
J Infect Dis. Author manuscript; available in PMC 2018 November 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Churchyard et al. Page 13
A
bb
re
v
ia
tio
ns
: a
H
R,
 a
dju
ste
d h
aza
rd 
rat
io;
 aR
R,
 ad
jus
ted
 ra
te 
rat
io;
 C
I, c
on
fid
en
ce
 in
te
rv
al
; C
RT
,
 
cl
us
te
r r
an
do
m
iz
ed
 tr
ia
l; 
EC
F,
 
en
ha
nc
ed
 c
as
e 
fin
di
ng
; H
IV
,
 
hu
m
an
 im
m
un
od
ef
ic
ie
nc
y 
vi
ru
s; 
IP
T,
 
iso
ni
az
id
 
pr
ev
en
tiv
e 
th
er
ap
y;
 M
. t
ub
er
cu
lo
sis
,
 
M
yc
ob
ac
ter
iu
m
 tu
be
rc
ul
os
is;
 R
R
, r
at
e 
ra
tio
.
J Infect Dis. Author manuscript; available in PMC 2018 November 03.
